Figure 6
Figure 6. UA does not prevent increased T-cell immunity induced by other means. (A) The peripheral levels of Tregs (CD4+CD25+Foxp3+ or CD8+CD25+Foxp3+) in animals injected with dying tumor cells alone (T) or with tumor cells with UA (T + UA). Each bar is the mean (± SEM; *P < .05) of 3 mice. (B) Levels of neu peptide tetramer+ CD8+CD62Llo T cells (ie, effector or effector memory) in control animals, or animals injected with tumor cells (T) with or without UA (UA) or ONTAK (On). Each bar is the mean (± SEM) of 3 to 4 mice. (C) The tumor growth rates in mice pretreated with tumor cells alone and tumor cells with or without UA, ONTAK, or both. Each data point is the mean (± SEM) of 3 to 5 mice. *P < .05 compared with all other groups.

UA does not prevent increased T-cell immunity induced by other means. (A) The peripheral levels of Tregs (CD4+CD25+Foxp3+ or CD8+CD25+Foxp3+) in animals injected with dying tumor cells alone (T) or with tumor cells with UA (T + UA). Each bar is the mean (± SEM; *P < .05) of 3 mice. (B) Levels of neu peptide tetramer+ CD8+CD62Llo T cells (ie, effector or effector memory) in control animals, or animals injected with tumor cells (T) with or without UA (UA) or ONTAK (On). Each bar is the mean (± SEM) of 3 to 4 mice. (C) The tumor growth rates in mice pretreated with tumor cells alone and tumor cells with or without UA, ONTAK, or both. Each data point is the mean (± SEM) of 3 to 5 mice. *P < .05 compared with all other groups.

Close Modal

or Create an Account

Close Modal
Close Modal